The Gut and Skin Microbiome in Vitiligo Disease Progression
Northwestern University · NCT03577327
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–89 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- May 30, 2019
- Record last updated
- June 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.
Conditions: Vitiligo; Healthy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patients with and/or without vitiligo lesional expansion over the past year.
- Age/sex-matched controls who do not have a diagnosis of vitiligo
- Subjects who are age 18-89 years of age at time of enrollment
- Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443)
Exclusion Criteria
- Subjects who are younger than 18 years of age or 90 years of age or older
- Subjects who are unable to give consent
Recruiting US locations
Northwestern University
Chicago, IL 60611
Site contact: Dermatology CTU · 312-503-5944 · NUdermatologyCTU@northwestern.edu
Study contacts (from the official record)
- Dermatology CTU · 312-503-5944 · NUdermatologyCTU@northwestern.edu
Similar studies in Illinois
All dermatology studies in Illinois →- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Rolling Meadows, IL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Skokie, IL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Normal, IL + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Chicago, IL + 28 other US sites
- Eligibility basics
- Ages 12+